Clinical Trial Update: A Clinical Pharmacology Study of K-877 Controlled Release Tablet [Phase 2]

View source ↗

Summary

A completed Phase 2 clinical pharmacology study of the controlled-release tablet form of K-877 (pemafibrate) for dyslipidemias.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias

Drugs mentioned

• K-877 (pemafibrate)

Snippet

Sponsor: Kowa Company, Ltd. | Conditions: Dyslipidemias | Phase 2 | Status: COMPLETED